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Introduction
Mobile Airways Sentinel NetworK (MASK) is a Good 
Practice of DG Santé on digital  tools for cit izen 
empowerment and person-centred care for rhinitis and 
asthma multimorbidity. It was presented in the Joint 
Research Centre of Ispra (December 15, 2018) (1-5). 
MASK is based on: 
 An App for rhinitis and asthma developed by the 
MACVIA-France EIP on AHA reference site 
(Allergy Diary, now MASK-air®), available in 27 
countries and fully validated (1); 
 An interoperable electronic clinical decision 
support system (CDSS) (6); 
 A n  i n t e r o p e r a b l e  w e b - b a s e d  p h y s i c i a n ’s 
questionnaire (7) and 
 An EIT Health project POLLAR (Impact of 
air POLLution on Asthma and Rhinitis) which 
predicts alerts for pollen and pollution peaks (8).
MASK has led to:
 A better understanding of rhinitis in terms of 
phenotypes and management (1,9);
 A better understanding of the links between allergy 
and pollution (10,11);
 A proof-of-concept on the digital transformation of 
health and care to sustain Planetary Health (12);
 Clinical trials (13,14).
MASK is embedded in the European Union (EU) 
political agenda (15) and is aimed at strengthening the EU 
digital single market (DSM) (16).
A first Twinning [success story of Digital Health Europe 
(DHE)] was devoted to rhinitis and asthma. It included 22 
reference sites and 22 countries (8). Over 1,000 patients 
were enrolled. The aim of the first Twinning was to transfer 
innovation from the MASK-air® App to other reference 
sites on rhinitis across the life cycle. The analyses of the 
data using artificial intelligence are underway.
Severe asthma (SA) is an important global health 
problem leading to exacerbations, deaths and resource 
utilization. Over 80% of direct and indirect asthma costs 
are incurred by SA. Its phenotype and treatment in old age 
adults are poorly understood. Less than 5% of asthmatic 
patients have SA and only collaborative studies can have a 
sufficient number of participants to perform pooled analyses 
in order to better phenotype and manage the disease, thanks 
to the large scale-up allowed by validated digital solutions.
Building on the experience of the first Twinning, (8) the 
DHE Twinning on SA was planned to form a European 
network of experts on SA. The kick-off meeting of the 
DHE Twinning was organized at the Institut Pasteur, Paris, 
January 10, 2020. This meeting was jointly sponsored by 
ARIA and the Reference Site Collaborative Network of the 
European Innovation Partnership on Active and Healthy 
Ageing (17). It was a GARD research demonstration project 
following the two meetings held in the same venue in 2019 
(18,19).
The current paper reports the minutes of the meeting. 
New concepts of allergic multimorbidity 
Allergic diseases are heterogeneous. Clinically, some patients 
have allergic rhinitis (AR) alone, whereas others have AR 
and asthma (with or without other allergic manifestations). 
Few patients have asthma alone, particularly in childhood. 
There are common genes in asthma and AR multimorbidity 
[e.g., IL-33: T2 inflammation (20) and IL-5: eosinophil 
activation (21)], and specific genes in AR alone (TLR). 
Moreover, ocular symptoms add further complexity to the 
allergy phenotypes (22) and to SA (23). By combining big 
data analyses [MASK (3)], classical epidemiologic studies, 
in silico analyses, transcriptomics [MeDALL (21,24,25)] and 
gene sequencing (26), the mechanisms of allergic diseases 
have been reclassified. In particular, polysensitization and 
multimorbidity represent the extreme allergic phenotype, 
starting early in life and with the greatest severity. This is 
associated with IL-5 and IL-33 activation. It is classically 
proposed that rhinitis can lead to asthma. However, the 
exact phenotype of AR prone to developing asthma is still 
unclear. It is possible that polysensitized individuals can 
more commonly develop lower airway symptoms. These 
considerations should be included in any study on SA to 
better define phenotypes and severity.
DHE Twinning
The focus of the Twinning is on local, regional and national 
health and care providers in Europe that wish to adopt 
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innovative solutions which are available for transfer from 
elsewhere. Applying to the tender opportunities of European 
calls for Horizon 2020, this provides an opportunity to share 
the experience with a large number of experts in SA and its 
different shapes, using MASK-air® data across Europe. 
Some of the principal aspects will be proposed to 
improve the innovative aspect of care by digital medicine on 
the severe shape of asthma. The innovative study will assess 
different contributors of SA such as climate change and air 
pollution (27), psychological aspects as well as the impact of 
stress on SA (28), and, finally, the adherence (29) and use of 
devices. 
Aims of the Severe Asthma-Twinning: using:
 The expertise of the first Twinning (8); 
 The  World  Heal th  Organizat ion  (WHO) 
classification of SA (30); 
 The addition of new questions relevant to SA in the 
MASK-air® app as well as the web-based physician’s 
questionnaire;
 Previous Twinning members with a high patient 
inclusion rate and including new members.
The general aim of the DHE Twinning is to form a 
network that will reduce the burden of SA, particularly in 
old age people.
The specific objectives are:
(I) To form an international network for SA in old age 
people globally;
(II) To better understand the phenotype and treatment 
of SA in old age people with possible differences 
between countries and gender;
(III) To include the results into the Good Practice 
on Digital Health for disease stratification and 
personalized health care. With a vision to better 
prescribe expensive treatments (biologics) and 
to follow-up the patients using real-world data 
analyzed as previously in MASK-air® and with 
artificial intelligence as a proof-of-concept;
(IV) To be the basis for a further deployment beyond 
the funding, including a network of centres of 
excellence (CoE) on SA (ARIACare for severe 
asthma) through an interdisciplinary collaboration 
and with the involvement of primary care and 
patients’ organisations.
MASK e-platform for shared decision-making 
(SDM) in airway diseases
In SDM, both the patient and the physician contribute to 
the process, placing the patient at the centre of the medical 
decision-making (31). mHealth applications and other 
e-tools support SDM (32). The MASK e-platform for SDM 
in airway diseases is being developed around MASK to allow 
a uniform and harmonized assessment of airway diseases. 
It has already added other validated tools [e.g., the Control 
of Allergic Rhinitis and Asthma Test (CARAT) (33-35) 
or Air Quality (8,11)] and will be open to integration of 
third-party features or functionalities. Privacy and personal 
data protection are also a core requirement, building on the 
previous work done for the MASK-air® app (36,37).
The platform will be used for several purposes and will 
use four scenarios:
 The screening of patients when they use the 
project’s app, either in the waiting room or in the 
physician’s office;
 The initial assessment of the patient for the 
diagnosis and treatment of allergic disease using a 
physician’s web-based questionnaire and a CDSS;
 The follow-up of the patient using the updated 
MASK-air® app and additional tools depending on 
the needs;
 The review of the patient by a healthcare 
professional after a period of follow-up.
The components of the e-platform will include (I) the 
MASK-air® app, (II) CARAT, COPD and comorbidities 
screening questionnaires; (III) an e-CDSS for AR and 
asthma; (IV) lung function monitoring and personalized 
behaviour recommendations; (V) the Twinning Physician 
questionnaire; (VI) INSPIRERS’ verified inhaler adherence 
and gamification (38) and (VII) air quality and pollen 
information. 
ARIACARE CoE
ARIA (Allergic Rhinitis and its Impact on Asthma) was 
established 20 years ago and includes over 600 members in 
over 80 countries (1). ARIA Phase 3 was the development 
of a Good Practice on the digital transformation of health 
and care in rhinitis and asthma. In ARIA Phase 4 (change 
management for airway diseases) (3,39), a network of CoE is 
being organized. ARIACARE is part of the GA2LEN CoE 
and includes UCARE and ADCARE (40). Accreditation 
follows the UCARE proposals and ARIA members will be 
able to apply. Other CoE can also apply to ARIACARE. 
ARIACARE-Digital is a novel network whose aim is to 
implement the digital transformation of health and care 
in airway diseases. Both members of MASK and others 
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can join this network. ARIACARE-Digital has links with 
GA2LEN (41) but both are independent. Three levels of 
centres are proposed (regular, gold and platinum) with a 
review each year. Numerous benefits are expected from this 
innovation.
Web-based physician’s questionnaire
In order to have a common assessment of the patients, a 
web-based physician’s questionnaire has been developed 
from the rhinitis questionnaire and is available in 17 
languages (8). The rhinitis questionnaire includes CARAT 
(33-35). The asthma questionnaire includes the questions 
already available for rhinitis, and questions pertinent to 
asthma have been added:
 Level of total IgE;
 Asthma risk factors;
 Etiology of asthma;
 Family history of allergy;
 Multi-morbidities: allergic, non-allergic and 
chronic diseases;
 Spirometry;
 Markers of T2 and inflammation (FeNO and blood 
eosinophils);
 Optional: CT scan.
Results of the Twinning rhinitis and asthma
Over 1,000 patients have been included in the Twinning for 
rhinitis and asthma (8) and some data have been analyzed (8).
A cross-sectional study on 958 patients with AR in 
9 countries used a web-based physician’s questionnaire 
interoperable with the MASK-air® app. Allergists initially 
recorded the diagnosis of allergy that had been made 
(rhinitis, rhinoconjunctivitis, current or past asthma) and 
then used the CARAT questionnaire. Patients were then 
asked to use the MASK-air® app, and asthma was assessed 
on the first day of reporting using a visual analogue scale 
(VAS) and treatments. This is the first study to assess a 
physician’s diagnosis of asthma in AR using electronic real-
world data (RWD). The current asthma under-diagnosis 
was found to be substantial in very experienced and 
committed allergists. Asthma control was better in CARAT-
diagnosed asthma than in physician’s reported asthma. 
There is a need for an electronic screening tool to diagnose 
asthma in rhinitis patients (in preparation). 
Another study examined the adherence of patients, and a 
low adherence was observed for both asthma and rhinitis (in 
preparation).
The role of patient’s organisations in SA 
The European Federation of Allergy and Airways Diseases 
Patients’ Associations (EFA) has identified some of the 
challenges and needs for SA patients to raise awareness on 
the impact of SA in patients’ lives. First, it is vital to have 
a timely and accurate diagnosis. Many patients wait for 
years before knowing their subtype of asthma and getting a 
tailored and more effective treatment. According to a recent 
study (42) conducted by EFA, 21% of people with SA wait 
for more than 5 years to obtain an accurate diagnosis. 
Treatments have improved and new drugs (biologics) 
are changing the life of patients with SA, despite only a 
few of them currently undergoing these treatments (9% 
according to the EFA study). Patient involvement in 
research is key to improving clinical outcomes, phenotyping 
SA and taking full advantage of personalized medicine. 
Patients with SA are more keen to be involved in research 
compared to patients with moderate or mild asthma, but 
their involvement is still low (77% have not taken part in 
research; 44% are not willing to share their medical data for 
research). 
Finally, the support of family, friends, and other patients 
can provide motivation in the adherence to treatment. 
Parents or carers of people with SA need to know how to 
cope with the disease, and their education is essential for 
good care. However, in most of the cases (70%), they do 
not receive adequate training. 
Artificial intelligence and advanced data 
management
Recent years have witnessed the resurgence of artificial 
intelligence and machine learning in many fields of 
knowledge, not least in health care. Amongst the most 
promising research directions in the broad field of artificial 
intelligence, three distinct methodological lines are being 
explored for their potential use in health studies, including 
asthma research.
F i r s t l y,  deep  l ea rn ing ,  and  par t i cu l a r l y  deep 
convolutional neural networks, have proven their value in 
many applications. Recent methodological developments 
and the availability of large databases have led to human-
like performance in tasks such as image analysis, including 
medical imaging (43) and natural language processing (e.g., 
for the analysis of clinical histories).
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More general machine learning techniques, such as 
manifold learning, can be used to make sense of large and 
heterogeneous datasets, such as the ones involved in clinical 
studies. Examples of these techniques and their application 
to medical datasets have been shown (44). This strategy 
seems particularly suited for the multifactorial study of 
rhinitis and asthma, and is being developed in our on-going 
research.
Finally, reinforcement learning approaches can be 
used to simulate populations and optimize policies [or to 
automatically play games such as Go (45)]. In the field of 
health care and epidemiology, the combination of these 
simulations with manifold learning is a very promising line 
of research.
Registries of SA
Clinical practice requires a complex interplay between 
experience and training, research, guidelines and 
judgement. It must draw not only on data from traditional 
or classical randomized controlled trials (RCTs), but also 
from pragmatically designed studies that better reflect real-
life clinical practice. 
To minimize extraneous variables and to optimize 
their internal validity, RCTs exclude patients, clinical 
characteristics and variations in care that could potentially 
confound outcomes. The result is that respiratory RCTs 
often enroll a small, non-representative subset of patients 
and overlook the important interplay and interactions 
between patients and the real world, which can affect 
treatment outcomes.
Evidence from real-l i fe studies (pragmatic and 
observational clinical trials) can be combined with RCT 
evidence to provide a fuller picture of intervention 
effectiveness and realistic treatment outcomes.
In developing a real-world evidence (RWE) programme, 
it is fundamental to distinguish between the sources of 
RWD and the evidence derived from that data. Evaluating 
RWE in the context of regulatory decision-making depends 
not only on the evaluation of the methodologies used 
to generate the evidence but also on the reliability and 
relevance of the underlying RWD. These constructs may 
raise different types of consideration. 
Patient registries are a good quality source of RWD that 
could be used to generate RWE. A patient registry is an 
organized system that uses observational study methods to 
collect uniform data (clinical and other) in order to evaluate 
specified outcomes for a population defined by a particular 
disease, condition, or exposure and that serves one or 
more predetermined scientific, clinical, or policy purposes. 
Their fitness for use in generating RWE requires sufficient 
processes, such as those to gather follow-up information 
when needed, to ensure data quality, and to minimize 
missing or incomplete data. 
Regional and/or national SA registries provide valuable 
country-specific information (46-49). However, they are 
often limited in scope within the broader definitions of SA, 
have insufficient statistical power to answer many research 
questions, lack intra-operability to share lessons learned, 
and have fundamental differences in data collected, making 
cross comparisons difficult. 
A worldwide registry could bring all SA data together 
in a cohesive way, under a single umbrella, based on 
standardized data collection protocols, permitting data to 
be shared seamlessly. The International Severe Asthma 
Registry (ISAR) is the first global adult SA registry. It is a 
joint initiative where national registries retain ownership of 
their own data but open their borders and share data with 
ISAR for ethically approved research purposes. Its strength 
comes from the collection of patient-level, anonymous, 
longitudinal, real-life, standardized, high-quality data 
(using a core set of variables) from countries across the 
world, combined with organizational structure, database 
experience, inclusivity/openness, and clinical, academic, 
and database expertise. This provides data with sufficient 
statistical power to answer important research questions, 
sufficient data standardization to compare across countries 
and regions, and the structure and expertise necessary 
to ensure its continuance and the scientific integrity and 
clinical applicability of its research. 
Country-based RWD: Finland
Finland has developed a very extensive health system and 
can be considered as a pioneered country for RWD. Some 
examples are given in this paper (50-53).
National Register Data
 Administrative registers in Finland use a unique 
personal identification number assigned to each 
resident (since 1964).
 National registers include health-related data on: 
 Causes of death; 
 Treatment periods and diagnoses (ICD-10) in 
hospitals; 
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 Diagnoses in primary health care arranged by 
the public sector (ICD-10, ICPC); 
 Reimbursed and other prescribed medications;
 Sickness benefits;
 Work disability pensions and the diagnoses;
 Cancer.
 Most of the relevant registers are maintained by the 
Finnish Institute for Health and Welfare (THL), 
Statistics Finland and the National Social Insurance 
Institution (KELA).
 The coverage of register data is quite good in selected 
diseases, but poor in others (Table 1).
Register data in North Karelia 
North Karelia is one of the 20 hospital districts in Finland. 
It includes 14 municipalities and a population of 163,000.
 Health and social services are organized by Siun 
sote which is a joint municipal authority of social 
and health services in the region;
 There is one central hospital and 22 health stations 
in the region;
 Since 2010, a joint electronic health record (EHR) 
has been in use in the region covering both primary 
and secondary level care;
 EHR is structural in format, enabling easy data 
retrieval. The database is administered by the 
North Karelia IT-Center and the Siun sote 
reporting unit;
 The EHR database includes information on all 
visits to both primary and specialized care services, 
stays at wards in health centres or hospitals, clinical 
procedures and investigations, laboratory tests and 
prescriptions;
 The coverage of recorded diagnoses on physician 
visits is almost 100%. All laboratory test results are 
recorded in the database directly by the laboratory 
service provider (one accredited organization in the 
whole region) and results of clinical investigations 
such as clinico-physiological tests (e.g., spirometry) 
are recorded in the database in structural format;
 The data are already widely used in analyzing 
outcomes of care in the region and in developing 
quality of care reporting systems.
National Health Surveys (https://thl.fi/en/web/thlfi-en/
statistics/information-on-statistics)
These include:
 Interview/questionnaire surveys (HIS), annual since 
the 1970s;
 Comprehensive health examination surveys (HES) 
since the 1970s;
 Population-based sample, generally around 
10,000 subjects;
 Most HES-surveys include interviews and 
questionnaires, personal health examinations 
with physical measurements and blood 
samples as well as functional capacity tests;
 All HES-surveys include questions on asthma: 
symptoms, treatment;
 Selected HES-surveys include spirometry 
(with or without bronchodilatation).
 All health surveys include a register-based follow-
up of deaths, hospital care, drug purchases, 
entitlements to specially reimbursed medication, 
sickness benefits, work disability pensions, etc.
DSM and cross-border data exchange
Current demographic trends challenge the sustainability and 
equity of European health systems (54,55). A paradigmatic 
shift from reactive disease management to proactive care, 
that is developed around a citizen empowered to take part 
in the health plan, can possibly contribute to achieving 
a triple win for our Society: improved health outcomes, 
sustainability and development (56). 
Providing equitable public health services that are 
of high quality within a sustainability framework relies 
on digital innovation and cross-border interoperability. 
Therefore, in Europe, providing secure access to genomic 
and other health data among Member States is essential for 
better health and care delivery to European citizens. This is 
also pivotal in ensuring that the EU remains at the forefront 
of health research (57).
Public health systems throughout the EU have been 
Table 1 Prevalence of selected diseases in the population-based sample  
of the National Health Examination Survey (FinHealth 2017): 
comparison between two data sources: survey data and registers on 
the use of hospital and primary care
Diseases Survey Register Cohen’s Kappa
Hypertension 42.7 11.1 0.24
Diabetes 10.1 9.1 0.85
Asthma 8.6 7.3 0.71
Depression 6.7 2.4 0.37 
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making huge efforts to develop around citizens' needs. 
They are at the centre of service design, organization 
and provision. Data-driven healthcare innovation is 
effective when citizens play an active role in the set-
up of personalized treatment, respectful of their right 
to data privacy. In order to overcome data silos, lack of 
interoperability and fragmentation of initiatives across 
the EU, enhanced cooperation between member states is 
essential. 
The DSM strategy (58) aims to open up digital 
opportunities for people and businesses and to enhance 
Europe’s position as a world leader in the digital economy. 
It provides the possibility of implementing the Digital 
Transformation of Health and Care by:
 Scaling-up digital innovation through regional eco-
systems;
 Encouraging peer-adoptions of reference good 
practices;
 Promoting stronger connections across regions and 
cooperation in the field of active and healthy ageing 
(AHA).
The priorities identified by the DSM strategy are:
(I) Citizens’ access to health data: Focusses on citizens’ 
secure access to their health data, also when they 
are abroad. The goal is to enable citizens to exert 
their right to access their health data across the 
EU, including, inter alia, the interoperability of 
EHR systems;
(II) Personalized medicine through shared European 
data infrastructure. This stresses the importance of 
personalized medicine through a shared European 
data infrastructure; 
(III) Citizen empowerment and person-centred care. 
This empowers people to look after their health, 
stimulating prevention and enabling feedback and 
interaction between users and healthcare providers.
In order to achieve the DSM objectives, the European 
Commission (EC) has been supporting the EIP on AHA 
since 2013 (59). This horizontal Partnership includes 2 
main, interconnected strains:
 The reference sites (17);
 The thematic action groups (60);
The three main pillars of the partnership are:
 The blueprint on the Digital Transformation of 
Health and Care (61). MASK is an example of this 
strategy (16);
 The innovation to market strategy;
 A shared monitoring and assessment tool: the 
MAFEIP. 
The three  pi l lars  have been developed by the 
collaborative efforts of the partners. Tailored maturity 
patterns grounded on the exchange of good practices 
are currently progressing and are being developed by 
international expert clusters. They are being tailored to 
locoregional contexts to foster and speed up adoption. The 
partnership represents a key enabling factor in the scale 
up of innovative good practices such as MASK, that can 
mitigate the impact of chronic diseases.
Allergic diseases and asthma in older people 
According to the WHO, the population aged 65 and above 
is destined to double in number within the next 40 years, 
and respiratory pathologies are today the main cause of 
mortality in Europe and the US (62). Among the elderly, 
rhinitis is one of the most common chronic diseases, 
affecting 20% of the patients, with asthma rates ranging 
between 4% and 13%.
MASK implements information and communications 
technology (ICT) mobile technology via a mobile phone 
app which collects the daily data of VASs for overall allergic 
symptoms. The aim is to ensure an active and healthy life 
in older patients with rhinitis and asthma across their life 
cycle. The app has proven to be very useful in managing 
allergic respiratory diseases in the elderly, with great 
appreciation from its users. To implement the adoption 
of the app across the territory, we have built a network of 
allergists throughout the entire Apulian region, in which 
each provincial capital is home for a main network node, 
coordinating and supporting nodes operating in smaller 
cities (63). The main Italian Scientific Society of Allergists 
(SIAAIC) has been involved in the project with the aim 
to organize meetings in order to spread the message and 
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